1-5 of 5
Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)
Close
Sort by
Journal Articles

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

Clinical Trials & Observations
Gerwin Huls, Dana A. Chitu, Violaine Havelange, Mojca Jongen-Lavrencic, Arjan A. van de Loosdrecht, Bart J. Biemond, Harm Sinnige, Beata Hodossy, Carlos Graux, Rien van Marwijk Kooy, Okke de Weerdt, Dimitri Breems, Saskia Klein, Jürgen Kuball, Dries Deeren, Wim Terpstra, Marie-Christiane Vekemans, Gert J. Ossenkoppele, Edo Vellenga, Bob Löwenberg, the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)
Journal: Blood
Blood (2019) 133 (13): 1457–1464.
https://doi.org/10.1182/blood-2018-10-879866
Published: 2019
Includes: Supplemental data
Journal Articles

Autologous peripheral blood stem cell transplantation for acute myeloid leukemia

Clinical Trials & Observations
Edo Vellenga, Wim van Putten, Gert J. Ossenkoppele, Leo F. Verdonck, Matthias Theobald, Jan J. Cornelissen, Peter C. Huijgens, Johan Maertens, Alois Gratwohl, Ron Schaafsma, Urs Schanz, Carlos Graux, Harry C. Schouten, Augustin Ferrant, Mario Bargetzi, Martin F. Fey, Bob Löwenberg, for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), and Swiss Group for Clinical Cancer Research Collaborative Group (SAKK)
Journal: Blood
Blood (2011) 118 (23): 6037–6042.
https://doi.org/10.1182/blood-2011-07-370247
Published: 2011
Includes: Supplemental data
Journal Articles

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

Clinical Trials & Observations
Bob Löwenberg, Joachim Beck, Carlos Graux, Wim van Putten, Harry C. Schouten, Leo F. Verdonck, Augustin Ferrant, Pieter Sonneveld, Mojca Jongen-Lavrencic, Marie von Lilienfeld-Toal, Bart J. Biemond, Edo Vellenga, Dimitri Breems, Hilde de Muijnck, Ron Schaafsma, Gregor Verhoef, Hartmut Döhner, Alois Gratwohl, Thomas Pabst, Gert J. Ossenkoppele, Johan Maertens, for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), German Austrian AML Study Group (AMLSG), Swiss Group for Clinical Cancer Research Collaborative Group (SAKK)
Journal: Blood
Blood (2010) 115 (13): 2586–2591.
https://doi.org/10.1182/blood-2009-10-246470
Published: 2010
Journal Articles

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

Clinical Trials & Observations
Bronno van der Holt, Bob Löwenberg, Alan K. Burnett, Wolfgang U. Knauf, John Shepherd, Pier Paolo Piccaluga, Gert J. Ossenkoppele, Gregor E. G. Verhoef, Augustin Ferrant, Michael Crump, Dominik Selleslag, Matthias Theobald, Martin F. Fey, Edo Vellenga, Margaret Dugan, Pieter Sonneveld, on behalf of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and the United Kingdom Medical Research Council (MRC)
Journal: Blood
Blood (2005) 106 (8): 2646–2654.
https://doi.org/10.1182/blood-2005-04-1395
Published: 2005
Journal Articles

The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients

Clinical Trials & Observations
Gert J. Ossenkoppele, Wilfried J. Graveland, Pieter Sonneveld, Simon M. G. J. Daenen, Douwe H. Biesma, Leo F. Verdonck, M. Ron Schaafsma, Petra H. M. Westveer, Godefridus J. Peters, Paul Noordhuis, Petra Muus, Dominik Selleslag, Bronnie van der Holt, Michel Delforge, Bob Löwenberg, Gregor E. G. Verhoef, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)
Journal: Blood
Blood (2004) 103 (8): 2908–2913.
https://doi.org/10.1182/blood-2003-07-2195
Published: 2004